MassBiologics and the Wadsworth Center teamed up to generate a panel of RBD-specific antibodies (“nanobodies” or VHHs) that can be used for identity tests in the manufacture of SARS-CoV-2 subunit vaccines.
MassBiologics used yeast-display technologies to identify nanobodies specific for each RBD VoC, while Wadsworth Center evaluated the nanobodies’ suitability to function in mock identity tests with drug substances and drug products.
• GLP-grade quality SARS-CoV-2 RBD protein antigens from wild type, Beta, Delta, and Omicron variants were produced and purified at milligram quantities.
• A panel of VoC-specific VHH-IgG antibodies against SARS-CoV-2 RBD spike protein were identified and characterized for binding affinity (ELISA, BLI), SARS-CoV-2 neutralization, and epitope class.
• Developed SOPs for RBD and RBD adsorbed binding assays
MassBiologics and the Wadsworth Center developed critical reagents for use in developing analytical CMC assays involved in the manufacturing of SARS-CoV-2 subunit vaccines, which can help accelerate the manufacturing process.
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
New York State Department of Health (Wadsworth Center)
University of Massachusetts System
